

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
117P/PCT2/USAPPLICATION NO.  
10/529,431INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT  
PREVOST, G. et al.FILING DATE  
March 25, 2005GROUP/EXAMINER  
Unknown/Unknown

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
ESO	A	01/64197		PCT			
ESO	B	00/39130		PCT			
ESO	C	97/30053		PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ESO	D	O'BYRNE, K. J. et al., "A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer," Br. J. Cancer, 2002, 87:15020.					
ESO	E	VICAT, J-M. et al., "Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor," Biochem. Pharmacology, 2003, 65:423-433.					

EXAMINER

/Eric Olson/

DATE CONSIDERED

12/04/2006

